
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd has seen a positive shift in revenue estimates, particularly for IMVT-1402 in Graves' Disease, following successful updates from recent meetings. The company’s drug candidate Brepocitinib is demonstrating a significant advancement in dosing convenience over existing therapies, which positions it favorably in the marketplace and aligns with the growing investor confidence in its clinical success. Additionally, the promising results from the Phase 3 VALOR study for Brepocitinib underline its broad efficacy in treating moderate-to-severe dermatomyositis, enhancing Roivant's overall growth outlook and positioning it well against increasing competition in the biopharmaceutical space.
Bears say
Roivant Sciences faces significant challenges stemming from the failure of multiple drug candidates, including IMVT-1402 and brepocitinib, in clinical trials, which raises concerns about the viability of its pipeline and future revenue growth. Additionally, the risks associated with off-target effects from its drug mechanisms, as highlighted by key opinion leaders, suggest potential efficacy and safety issues that could hinder regulatory approvals. These setbacks, combined with ongoing unmet medical needs in the conditions they aim to treat, contribute to a pessimistic outlook on the company's financial health and stock performance.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares